Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling

Frontiers in Physiology

Volumn 3 JUL, Issue , 2012, Pages

  Kranstuber, Allyson L ^a   del Rio, Carlos ^b   Biesiadecki, Brandon J ^c,d   Hamlin, Robert L ^a,b   Ottobre, Joseph ^a   Gyorke, Sandor ^c,d   Lacombe, Veronique A ^a,e  

^a OHIO STATE UNIVERSITY   (United States)

^b QTest Labs   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Alagebrium chloride (ALT 711); Cardiomyopathy; Diastolic function; Sarcoplasmic reticulum Ca 2+ atpase pump; Type 1 diabetes

Indexed keywords

EID: 84866470030     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00292     Document Type: Article

References (39)

1. Amos, A. F., McCarty, D. J., and Zimmet, P. (1997). The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 14, S1-S85.
2. Aronson, D. (2003). Cross-linking of glycated collagen in the pathogene-sis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21, 3-12.
3. Asif, M., Egan, J., Vasan, S., Jyothirmayi, G. N., Masurekar, M. R., Lopez, S., Williams, C., Torres, R. L., Wagle, D., Ulrich, P., Cerami, A., Brines, M., and Regan, T. J. (2000). An advanced glycation end product cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. U.S.A. 97, 2809-2813.
4. Aurigemma, G. P., Zile, M. C., and Gaasch, W. H. (2006). Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 113, 296-304.
5. Bakris, G. L., Bank, A. J., Kass, D. A., Neutel, J. M., Preston, R. A., and Oparil, S. (2004). Advanced glyca-tion end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 17, 23S-30S.
6. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198-205.
7. Bidasee, K. R., Nallani, K., Yu, Y., Cocklin, R. R., Zhang, Y., Wang, M., Dincer, U. D., Besch, H. R. Jr. (2003). Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52, 1825-1836.
8. 2+-ATPase. Diabetes 53, 463-473.
9. Boudina, S., and Abel, E. D. (2007). Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223.
10. Candido, R., Forbes, J. M., Thomas, M. C., Thallas, V., Dean, R. G., Burns, W. C., Tikellis, C., Ritchie, R. H., Twigg, S. M., Cooper, M. E., and Burrell, L. M. (2003). A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 92, 785-792.
11. 2+ signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 283, H1398-H1408.
12. Cooper, M. E. (2004). Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am. J. Hypertens. 17, 31S-38S.
13. Cooper, M. E., Thallas, V., Forbes, J., Scalbert, E., Sastra, S., Darby, I., and Soulis, T. (2000). The cross-link breaker, N-phenacylthiazolium bromide, prevents vascular advanced glycation end-product accumulation. Diabetologia 43, 660-664.
14. Dent, C. L., Bowman, A. W., Scott, M. J., Allen, J. S., Lisauskas, J. B., Janif, M., Wickline, S. A., and Kovacs, S. J. (2001). Echocardiographic characterization of fundamental mechanisms of abnormal diastolic filling in diabetic rats with a parameterized diastolic filling formalism. J. Am. Soc. Echocardiogr. 14, 1166-1172.
15. Dirksen, W. P., Lacombe, V. A., Chi, M., Kalyanasundaram, A., Viatchenko-Karpinski, S., Terentyev, D., Zhou, Z., Vedamoorthyrao, S., Li, N., Chiamvimonvat, N., Carnes, C. A., Franzini-Armstrong, C., Györke, S., and Periasamy, M. (2007). A mutation in calsequestrin CSQD307H impairs SR calcium storage and release functions and causes polymorphic ventricular tachycardia in mice. Cardiovasc. Res. 75, 69-78.
16. Fang, Z. Y., Prins, J. B., and Marwick, T. H. (2004). Diabetic cardiomy-opathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543-567.
17. Forbes, J. M., Yee, L. T., Thallas, V., Lassila, M., Candido, R., Jandeleit-Dahm, K. A., Thomas, M. C., Burns, W. C., Deemer, E. K., Thorpe, S. M., Cooper, M. E., and Allen, T. J. (2004). Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53, 1813-1823.
18. Hartog, J. W., Voors, A. A., Bakker, S. J., Smit, A. J., and van Veldhuisen, D. J. (2007). Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 9, 1146-1155.
19. Kubalova, Z., Terentyev, D., Viatchenko-Karpinski, S., Nishi-jima, Y., Györke, I., Terentyeva, R., da Cunha, D. N., Sridhar, A., Feldman, D. S., Hamlin, R. L., Carnes, C. A., and Györke, S. (2005). Abnormal intrastore calcium signaling in chronic heart failure. Proc. Natl. Acad. Sci. U.S.A. 102, 14104-14109.
20. Lacombe, V. A., Terentyev, D., Viatchenko-Karpinski, S., Hamlin, R. L., Györke, S., and Carnes, C. (2010). Diltiazem treatment attenuates arrhythmogenesis during diabetic cardiomyopathy by stabilizing ryanodine receptors-mediated sarcoplasmic reticulum calcium release (abstract). Circulation 122, A20958.
21. Lacombe, V. A., Viatchenko-Karpinski, S., Terentyev, D., Sridhar, A., Emani, S., Bonagura, J. D., Feldman, D. S., Györke, S., and Carnes, C. A. (2007). Mechanisms of impaired calcium handling underlying sub-clinical diastolic dysfunction in diabetes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R1787-R1797.
22. 2+ handling in ventricular myocytes isolated from diabetic rats. Am. J. Physiol. 270, H1529-H1537.
23. Liu, J., Masurekar, M. R., Vatner, D. E., Jyothirmayi, G. N., Regan, T. J., Vatner, S. F., Meggs, L. G., and Malhotra, A. (2003). Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 285, H2587-H2591.
24. Ma, H., Li, S. Y., Xu, P., Babcock, S. A., Dolence, E. K., Brownlee, M., Li, J., and Ren, J. (2009). Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomy-opathy. J. Cell. Mol. Med. 13, 1751-1764.
25. Meurs, K., Lacombe, V. A., Dryburgh, K., Fox, P. R., and Kittleson, M. D. (2006). Differential expression of the cardiac ryanodine protein in normal dogs and boxer dogs with arrhythmogenic right ventricular cardiomyopathy. Hum. Genet. 120, 111-118.
26. 2+-cycling proteins may underlie sar-coplasmic reticulum dysfunction in the diabetic heart. Diabetes 50, 2133-2138.
27. Norton, G. R., Candy, G., and Woodiwiss, A. J. (1996). Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93, 1905-1912.
28. Piccini, J. P., Klein, L., Gheorghiade, M., and Bonow, R. O. (2004). New insights into diastolic heart failure: role of diabetes mellitus. Am. J. Med. 116, 64S-75S.
29. 2+ in the heart during diabetes. Cardiovasc. Res. 34, 41-47.
30. Poornima, I., Parikh, P., and Shannon, R. (2006). Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ. Res. 98, 596-605.
31. Ratnadeep, B., Gavin, O. Y., Xiuhua, W., Liyan, Z., John, U. R., Gary, L. D., and Zamaneh, K. (2009). Type 1 diabetic cardiomyopathy in Akita (Ins2 WT/C96Y) mouse model is characterized by lipotoxi-city and diastolic dysfunction with preserved systolic function. Am. J. Physiol. Heart Circ. Physiol. 297, H2096-H2108
32. 2+ release in myocytes from streptozotocin-induced diabetic rats. J. Mol. Cell. Cardiol. 42, 234-246.
33. Su, H. M., Lin, T. H., Voon, W. C., Lee, K. T., Chu, C. S., Lai, W. T., and Sheu, S. H. (2006). Differentiation of left ventricular diastolic dysfunction, identification of pseudonormal/restrictive mitral inflow pattern and determination of left ventricular filling pressure by Tei index obtained from tissue Doppler echocardiography. Echocardiography 23, 287-294.
34. Vaitkevicius, P. V., Lane, M., Spurgeon, H., Ingram, D. K., Roth, G. S., Egan, J. J., Vasan, S., Wagle, D. R., Ulrich, P., Brines, M., Wuerth, J. P., Cerami, A., and Lakatta, E. G. (2001). A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. U.S.A. 98, 1171-1175.
35. van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J., Schalkwijk, C. G., Bronzwaer, J. G., Diamant, M., Borbély, A., van der Velden, J., Stienen, G. J., Laarman, G. J., Niessen, H. W., and Paulus, W. J. (2008). Diastolic stiffness of the failing diabetic heart. Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43-51.
36. Vasan, S., Foiles, P., and Founds, H. (2003). Therapeutic potential of breakers of advanced glyca-tion end product-protein crosslinks. Arch. Biochem. Biophys. 419, 89-96.
37. Ware, B., Bevier, M., Nishijima, Y., Rogers, S., Carnes, C. A., and Lacombe, V. A. (2011). Chronic heart failure selectively induces regional heterogeneity of insulin-responsive glucose transporters. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R1300-R1306.
38. Wolffenbuttel, B. H., Boulanger, C. M., Crijns, F. R., Huijberts, M. S., Poitevin, P., Swennen, G. N., Vasan, S., Egan, J. J., Ulrich, P., Cerami, A., and Levy, B. I. (1998). Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U.S.A. 95, 4630-4634.
39. Zhong, Y., Ahmed, S., Grupp, I. L., and Matlib, M. A. (2001). Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am. J. Physiol. Heart Circ. Physiol. 281, H1137-H1147.